✦ LIBER ✦

Antibody-targeted chemotherapy of acute myeloid leukemia using gemtuzumab ozogamicin (Mylotarg)

✍ Scribed by Eric L. Sievers

Book ID: 117726531
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 195 KB
Volume: 31
Category: Article
ISSN: 1079-9796
DOI: 10.1016/s1079-9796(03)00117-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Antibody-targeted chemotherapy of older

Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)

✍ Larson, R A; Boogaerts, M; Estey, E; Karanes, C; Stadtmauer, E A; Sievers, E L; 📂 Article 📅 2002 🏛 Nature Publishing Group 🌐 English ⚖ 163 KB

Trials with Gemtuzumab Ozogamicin (Mylot

Trials with Gemtuzumab Ozogamicin (Mylotarg®) Combined with Chemotherapy Regimens in Acute Myeloid Leukemia

✍ Stadtmauer, Edward A. 📂 Article 📅 2002 🏛 CIG Media Group, LP. 🌐 English ⚖ 115 KB

Gemtuzumab Ozogamicin (Mylotarg) for the

Gemtuzumab Ozogamicin (Mylotarg) for the Treatment of Acute Myeloid Leukemia – Ongoing Trials

✍ Gleissner, Beate ;Schlenk, Richard ;Bornhäuser, Martin ;Berdel, Wolfgang E. 📂 Article 📅 2007 🏛 S. Karger AG 🌐 English ⚖ 122 KB

Early Phase I/II Trials with Gemtuzumab

Early Phase I/II Trials with Gemtuzumab Ozogamicin (Mylotarg®) in Acute Myeloid Leukemia

✍ Nabhan, Chadi; Tallman, Martin S. 📂 Article 📅 2002 🏛 CIG Media Group, LP. 🌐 English ⚖ 111 KB

Acute and Long-Term Toxicities Associate

Acute and Long-Term Toxicities Associated with Gemtuzumab Ozogamicin (Mylotarg®) Therapy of Acute Myeloid Leukemia

✍ Leopold, Lance H.; Berger, Mark S.; Feingoldr, Jay 📂 Article 📅 2002 🏛 CIG Media Group, LP. 🌐 English ⚖ 112 KB

Gemtuzumab ozogamicin in the treatment o

Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia

✍ Francis Giles; Elihu Estey; Susan O'Brien 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 484 KB 👁 2 views

## Abstract Gemtuzumab ozogamicin (GO) is a chemotherapeutic agent that consists of a humanized anti‐CD33 antibody (hP67.6) linked to N‐acetyl‐γ calicheamicin 1,2‐dimethyl hydrazine dichloride, a potent enediyne antitumor antibiotic. GO was approved conditionally by the Federal Drug Administration